Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.

Bernier C, Soliman A, Gravel M, Dankner M, Savage P, Petrecca K, Park M, Siegel PM, Shore GC, Roulston A.

Anticancer Drugs. 2018 Sep;29(8):774-785. doi: 10.1097/CAD.0000000000000653.

2.

Author Correction: Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo.

Liu H, Su D, Zhang J, Ge S, Li Y, Wang F, Gravel M, Roulston A, Song Q, Xu W, Liang JG, Shore G, Wang X, Liang P.

Sci Rep. 2018 Mar 22;8(1):5266. doi: 10.1038/s41598-018-23057-3.

3.

Assembly of Complex Macrocycles by Incrementally Amalgamating Unprotected Peptides with a Designed Four-Armed Insert.

Curtin BH, Manoni F, Park J, Sisto LJ, Lam YH, Gravel M, Roulston A, Harran PG.

J Org Chem. 2018 Mar 16;83(6):3090-3108. doi: 10.1021/acs.joc.7b02958. Epub 2018 Mar 7.

PMID:
29494773
4.

Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.

Cole J, Guiot MC, Gravel M, Bernier C, Shore GC, Roulston A.

Oncotarget. 2017 Sep 12;8(44):77846-77859. doi: 10.18632/oncotarget.20840. eCollection 2017 Sep 29.

5.

Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo.

Liu H, Su D, Zhang J, Ge S, Li Y, Wang F, Gravel M, Roulston A, Song Q, Xu W, Liang JG, Shore G, Wang X, Liang P.

Sci Rep. 2017 Aug 21;7(1):8953. doi: 10.1038/s41598-017-09518-1. Erratum in: Sci Rep. 2018 Mar 22;8(1):5266.

6.

Bereavement support standards and bereavement care pathway for quality palliative care.

Hudson P, Hall C, Boughey A, Roulston A.

Palliat Support Care. 2018 Aug;16(4):375-387. doi: 10.1017/S1478951517000451. Epub 2017 Jul 13.

PMID:
28701233
7.

The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity.

Wieczorek M, Tcherkezian J, Bernier C, Prota AE, Chaaban S, Rolland Y, Godbout C, Hancock MA, Arezzo JC, Ocal O, Rocha C, Olieric N, Hall A, Ding H, Bramoullé A, Annis MG, Zogopoulos G, Harran PG, Wilkie TM, Brekken RA, Siegel PM, Steinmetz MO, Shore GC, Brouhard GJ, Roulston A.

Sci Transl Med. 2016 Nov 16;8(365):365ra159. Erratum in: Sci Transl Med. 2017 Dec 20;9(421):.

8.

New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology.

Roulston A, Shore GC.

Mol Cell Oncol. 2015 Jun 10;3(1):e1052180. doi: 10.1080/23723556.2015.1052180. eCollection 2016 Jan. Review.

9.

Bereavement outcomes: A quantitative survey identifying risk factors in informal carers bereaved through cancer.

Roulston A, Campbell A, Cairnduff V, Fitzpatrick D, Donnelly C, Gavin A.

Palliat Med. 2017 Feb;31(2):162-170. doi: 10.1177/0269216316649127. Epub 2016 Jul 10.

PMID:
27170617
10.

Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.

Nguyen M, Cencic R, Ertel F, Bernier C, Pelletier J, Roulston A, Silvius JR, Shore GC.

BMC Cancer. 2015 Aug 1;15:568. doi: 10.1186/s12885-015-1582-5.

11.

Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.

Robert F, Roman W, Bramoullé A, Fellmann C, Roulston A, Shustik C, Porco JA Jr, Shore GC, Sebag M, Pelletier J.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13421-6. doi: 10.1073/pnas.1402650111. Epub 2014 Sep 2.

12.

Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.

Chan M, Gravel M, Bramoullé A, Bridon G, Avizonis D, Shore GC, Roulston A.

Cancer Res. 2014 Nov 1;74(21):5948-54. doi: 10.1158/0008-5472.CAN-14-0809. Epub 2014 Aug 21.

13.

Complementary therapy: perceptions of older people with lung or colorectal cancer.

Roulston A, Wilkinson P, Haynes T, Campbell J.

Int J Palliat Nurs. 2013 Jul;19(7):333-9.

PMID:
24273810
14.

Public awareness and attitudes toward palliative care in Northern Ireland.

McIlfatrick S, Hasson F, McLaughlin D, Johnston G, Roulston A, Rutherford L, Noble H, Kelly S, Craig A, Kernohan WG.

BMC Palliat Care. 2013 Sep 17;12(1):34. doi: 10.1186/1472-684X-12-34.

15.

Exploring public awareness and perceptions of palliative care: a qualitative study.

McIlfatrick S, Noble H, McCorry NK, Roulston A, Hasson F, McLaughlin D, Johnston G, Rutherford L, Payne C, Kernohan G, Kelly S, Craig A.

Palliat Med. 2014 Mar;28(3):273-80. doi: 10.1177/0269216313502372. Epub 2013 Sep 11.

PMID:
24026003
16.

BIM, PUMA, and the achilles' heel of oncogene addiction.

Roulston A, Muller WJ, Shore GC.

Sci Signal. 2013 Mar 26;6(268):pe12. doi: 10.1126/scisignal.2004113. Review.

PMID:
23532333
17.

Programming cancer cells for high expression levels of Mcl1.

Ertel F, Nguyen M, Roulston A, Shore GC.

EMBO Rep. 2013 Apr;14(4):328-36. doi: 10.1038/embor.2013.20. Epub 2013 Mar 12. Review.

18.

A pilot study to evaluate an outpatient service for people with advanced lung cancer.

Roulston A, Bickerstaff D, Haynes T, Rutherford L, Jones L.

Int J Palliat Nurs. 2012 May;18(5):225-33.

PMID:
22885859
19.

Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.

Dean EJ, Cummings J, Roulston A, Berger M, Ranson M, Blackhall F, Dive C.

Neoplasia. 2011 Apr;13(4):339-47.

20.

The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

Watson M, Roulston A, Bélec L, Billot X, Marcellus R, Bédard D, Bernier C, Branchaud S, Chan H, Dairi K, Gilbert K, Goulet D, Gratton MO, Isakau H, Jang A, Khadir A, Koch E, Lavoie M, Lawless M, Nguyen M, Paquette D, Turcotte E, Berger A, Mitchell M, Shore GC, Beauparlant P.

Mol Cell Biol. 2009 Nov;29(21):5872-88. doi: 10.1128/MCB.00112-09. Epub 2009 Aug 24.

21.

Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.

Beauparlant P, Bédard D, Bernier C, Chan H, Gilbert K, Goulet D, Gratton MO, Lavoie M, Roulston A, Turcotte E, Watson M.

Anticancer Drugs. 2009 Jun;20(5):346-54. doi: 10.1097/CAD.0b013e3283287c20.

PMID:
19369827
22.

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7. Epub 2007 Nov 26.

23.

Representing "grass roots" nurses at the top of the management ladder.

Roulston A.

Br J Community Nurs. 2005 Feb;10(2):82. No abstract available.

PMID:
15788948
24.

Viruses and apoptosis.

Roulston A, Marcellus RC, Branton PE.

Annu Rev Microbiol. 1999;53:577-628. Review.

PMID:
10547702
25.
26.

CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45.

Halenbeck R, MacDonald H, Roulston A, Chen TT, Conroy L, Williams LT.

Curr Biol. 1998 Apr 23;8(9):537-40.

27.

Activation of hPAK65 by caspase cleavage induces some of the morphological and biochemical changes of apoptosis.

Lee N, MacDonald H, Reinhard C, Halenbeck R, Roulston A, Shi T, Williams LT.

Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13642-7.

28.

Induction of relA(p65) and I kappa B alpha subunit expression during differentiation of human peripheral blood monocytes to macrophages.

Conti L, Hiscott J, Papacchini M, Roulston A, Wainberg MA, Belardelli F, Gessani S.

Cell Growth Differ. 1997 Apr;8(4):435-42.

30.

Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors.

Roulston A, Lin R, Beauparlant P, Wainberg MA, Hiscott J.

Microbiol Rev. 1995 Sep;59(3):481-505. Review.

31.

Subcellular redistribution of HTLV-1 Tax protein by NF-kappa B/Rel transcription factors.

Pepin N, Roulston A, Lacoste J, Lin R, Hiscott J.

Virology. 1994 Nov 1;204(2):706-16.

PMID:
7941339
32.

Viral induction of the human beta interferon promoter: modulation of transcription by NF-kappa B/rel proteins and interferon regulatory factors.

Garoufalis E, Kwan I, Lin R, Mustafa A, Pepin N, Roulston A, Lacoste J, Hiscott J.

J Virol. 1994 Aug;68(8):4707-15.

33.

Virus induction of NF-kappa B/Rel proteins and type I interferon gene expression in myelomonoblastic cells.

Roulston A, Conti L, McKiel V, Wainberg MA, Hiscott J.

Leukemia. 1994 Apr;8 Suppl 1:S170-4.

PMID:
8152286
34.

Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop.

Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G, et al.

Mol Cell Biol. 1993 Oct;13(10):6231-40.

35.
36.

Induction of monocytic differentiation and NF-kappa B-like activities by human immunodeficiency virus 1 infection of myelomonoblastic cells.

Roulston A, D'Addario M, Boulerice F, Caplan S, Wainberg MA, Hiscott J.

J Exp Med. 1992 Mar 1;175(3):751-63.

37.

Differential susceptibilities of U-937 cell clones to infection by human immunodeficiency virus type 1.

Boulerice F, Geleziunas R, Bour S, Li HL, D'Addario M, Roulston A, Hiscott J, Wainberg MA.

J Virol. 1992 Feb;66(2):1183-7.

38.
39.

Supplemental Content

Loading ...
Support Center